First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis "Phase 3 data showed treatment with SIMPONI ARIA plus ...

Golimumab 50mg/4mL; soln for IV infusion after dilution; preservative- and latex-free. Simponi Aria (golimumab) Injection is a colorless to light yellow solution available in packs of 1 vial. Each ...

Simponi Aria is available as a 50mg/4mL strength solution for IV infusion; it is administered as a 30-minute infusion. The Food and Drug Administration (FDA) has approved Simponi Aria® (golimumab; ...

Johnson & Johnson’s biotech arm, Janssen Biotech, received an expanded indication for its anti-TNF (tumor necrosis factor) infusion therapy, Simponi Aria (golimumab), for patients with ...

The US Food and Drug Administration (FDA) has approved golimumab (Simponi Aria, Janssen Biotech, Inc), intravenous (IV) formulation in combination with methotrexate, for the treatment of moderately to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Janssen Biotech announced that the FDA ...

HORSHAM, Pa., Sept. 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA ® ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its TNF inhibitor, Simponi Aria for the treatment of children 2 years and older with active polyarticular course juvenile ...

Johnson & Johnson 's JNJ subsidiary, Janssen Biotech, Inc. announced that it has submitted two Supplemental Biologics License Applications (sBLAs) in the U.S., seeking approval of Simponi Aria for the ...

Simponi is also prescribed to treat ulcerative colitis in adults. And Simponi Aria is also prescribed to treat PsA and polyarticular juvenile idiopathic arthritis in some children. Simponi and Simponi ...